Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Public ClinicalTrials.gov record NCT05737706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Study identification
- NCT ID
- NCT05737706
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Interventions
- MRTX1133 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2023
- Primary completion
- Mar 9, 2025
- Completion
- Mar 9, 2025
- Last update posted
- Apr 5, 2025
2023 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 311 | Phoenix | Arizona | 85054 | — |
| Local Institution - 309 | New Haven | Connecticut | 06520 8028 | — |
| Local Institution - 301 | Lady Lake | Florida | 32159 8987 | — |
| Local Institution - 306 | Baltimore | Maryland | 21231 | — |
| Local Institution - 308 | Boston | Massachusetts | 02114 3117 | — |
| Local Institution - 310 | Boston | Massachusetts | 02215 | — |
| Local Institution - 314 | Grand Rapids | Michigan | 49546 | — |
| Local Institution - 312 | New York | New York | 10065 6800 | — |
| Local Institution - 303 | Nashville | Tennessee | 37203 | — |
| Local Institution - 302 | Houston | Texas | 77030 | — |
| Local Institution - 304 | San Antonio | Texas | 78229 3307 | — |
| Local Institution - 313 | San Antonio | Texas | 78229 | — |
| Local Institution - 305 | Fairfax | Virginia | 22031 | — |
| Local Institution - 307 | Seattle | Washington | 98109 1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05737706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05737706 live on ClinicalTrials.gov.